Product Description: ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50s of 0.82 μM, 3 μM for ERK5 and ERK5 MEF2D, respectively. ERK5-IN-2 does not interact with the BRD4 bromodomain. ERK5-IN-2 suppresses both tumor xenograft growth and basic fibroblast growth factor (bFGF) driven Matrigel plug angiogenesis[1].
Applications: Cancer-Kinase/protease
Formula: C17H11BrFN3O2
References: [1]Myers SM, et al. Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4. Eur J Med Chem. 2019 May 25;178:530-543.
CAS Number: 1888305-96-1
Molecular Weight: 388.19
Compound Purity: 98.96
Research Area: Cancer; Cardiovascular Disease
Solubility: DMSO : 250 mg/mL (ultrasonic)
Target: ERK